Table 2.
Identified Tryptic Peptides for Holo‐ and Oxidized SAP30L
| No.a | Mass, exp. (Da)b | Mass, theor. (Da)b | Error (ppm) | Residues | Sequencec |
|---|---|---|---|---|---|
| holo‐SAP30L | |||||
| 1 | 529.3340 | 529.3336 | 0.76 | 28–31 | RVQK |
| 2 | 561.3127 | 561.3122 | 0.89 | 32–36 | SISQK |
| 3 | 602.3286 | 602.3275 | 1.74 | 40–44 | LDIDK |
| 4 | 689.4087 | 689.4072 | 2.18 | 32–37 | SISQKK |
| 5 | 843.5076 | 843.5066 | 1.19 | 38–44 | LKLDIDK |
| 6 | 862.4674 | 862.4661 | 1.51 | 57–63 | NFIQSVR |
| 7 | 944.5290 | 944.5291 | −0.11 | 40–47 | LDIDKSVR |
| 8 | 971.6018 | 971.6015 | 0.31 | 37–44 | KLKLDIDK |
| 9 | 1174.5613 | 1174.5594 | 1.62 | 48–56 | HLYICDFHK |
| 10 | 1185.7100 | 1185.7081 | 1.60 | 38–47 | LKLDIDKSVR |
| 11 | 1235.6101 | 1235.6081 | 1.62 | 16–27 | CVRPAGNASFSK |
| 12 | 1313.8041 | 1313.8031 | 0.76 | 37–47 | KLKLDIDKSVR |
| 13 | 1391.7116 | 1391.7092 | 1.72 | 16–28 | CVRPAGNASFSKR |
| 15 | 1615.6617 | 1615.6607 | 0.62 | 1–15 | GSYGQSCCLIEDGER |
| 16 | 2019.0169 | 2019.0149 | 0.99 | 48–63 | HLYICDFHKNFIQSVR |
| 22 | 2833.2641 | 2833.2582 | 2.08 | 1–27 | GSYGQSCCLIEDGERCVRPAGNASFSK |
| 23 | 2930.5968 | 2930.5926 | 1.43 | 48–70 | HLYICDFHKNFIQSVRNKRKRKT |
| 24 | 2945.5402 | 2945.5334 | 2.31 | 40–63 | LDIDKSVRHLYICDFHKNFIQSVR |
| 26 | 2989.3613 | 2989.3593 | 0.67 | 1–28 | GSYGQSCCLIEDGERCVRPAGNASFSKR |
| 27 | 3186.7203 | 3186.7125 | 2.45 | 38–63 | LKLDIDKSVRHLYICDFHKNFIQSVR |
| 28 | 3314.8165 | 3314.8074 | 2.75 | 37–63 | KLKLDIDKSVRHLYICDFHKNFIQSVR |
| 31 | 4769.6908 | 4769.6868 | 0.84 | 32–70 | SISQKKLKLDIDKSVRHLYICDFHKNFIQSVRNKRKRKT |
| oxidized SAP30L | |||||
| 1 | 529.3327 | 529.3336 | −1.70 | 28–31 | RVQK |
| 2 | 561.3114 | 561.3122 | −1.42 | 32–36 | SISQK |
| 3 | 602.3270 | 602.3275 | −0.83 | 40–44 | LDIDK |
| 4 | 689.4067 | 689.4072 | −0.73 | 32–37 | SISQKK |
| 5 | 843.5062 | 843.5066 | −0.47 | 38–44 | LKLDIDK |
| 6 | 862.4657 | 862.4661 | −0.46 | 57–63 | NFIQSVR |
| 7 | 944.5294 | 944.5291 | 0.41 | 40–47 | LDIDKSVR |
| 8 | 971.6012 | 971.6015 | −0.30 | 37–44 | KLKLDIDK |
| 10 | 1185.7066 | 1185.7081 | −1.27 | 38–47 | LKLDIDKSVR |
| 12 | 1313.8017 | 1313.8031 | −1.07 | 37–47 | KLKLDIDKSVR |
| 14 | 1613.6443 | 1613.6450 | −0.43 | 1–15 | GSYGQSCCLIEDGER (ox) |
| 17 | 2408.1505 | 2408.1518 | −0.54 | 16–27 + 48–56 | CVRPAGNASFSK + HLYICDFHK (ox) |
| 19 | 2564.2520 | 2564.2529 | −0.35 | 16–28 + 48–56 | CVRPAGNASFSKR + HLYICDFHK (ox) |
| 29 | 4003.7842 | 4003.7862 | −0.51 | 1–27 + 48–56 | GSYGQSCCLIEDGERCVRPAGNASFSK + HLYICDFHK (2ox) |
| 30 | 4159.8839 | 4159.8873 | −0.85 | 1–28 + 48–56 | GSYGQSCCLIEDGERCVRPAGNASFSKR+ HLYICDFHK (2ox) |
| 32 | 4848.2383 | 4848.2418 | −0.71 | 1–27 + 48–63 | GSYGQSCCLIEDGERCVRPAGNASFSK + HLYICDFHKIQSVR (2ox) |
a
For the peptides observed for holo‐SAP30L without DTT, see Supporting Information Table SI.
b
Monoisotopic mass. In case that the identified peptide appeared in multiple different charges states, an average value has been reported.
c
Oxidized cysteines in the sequences have been indicated by (ox) or (2ox).